San Francisco, United States
Cleave Therapeutics, Inc., founded in 2011, is a pioneering biopharmaceutical company headquartered in the United States. It focuses on developing VCP/p97 inhibitors for applications in oncology and neurodegenerative diseases. The company positions itself as a leader in targeting the valosin-containing protein, a promising and relatively untapped target in cancer stress pathways and cellular homeostasis.
The company's lead candidate, CB-5339, is a second-generation, potent, oral inhibitor aiming to advance treatment options in acute myeloid leukemia (AML) and solid tumors. Cleave's ongoing collaborations with renowned organizations like the National Cancer Institute and significant academic institutions bolster its scientific credibility and enhance research outcomes.
In its last funding round, Cleave raised $12.00M in Series C financing, attracting investors such as US Venture Partners, 5AM Ventures, OrbiMed, and Astellas Venture Management, highlighting solid financial backing and investor confidence.
